Skip to main content

Grafa News and Videos — Page 1077

Grafa Headlines

Latest

Grafa
Oil and Gas

Perma-Pipe revenue rises 7.5% as higher factory costs and compliance outlays squeeze profits

Perma-Pipe International Holdings (NASDAQ:PPIH) reported an expansion in top-line revenue for the first quarter of fiscal year 2026, driven by sustained industrial demand across its primary geographic footprints, though near-term factory start-up friction and heightened regulatory compliance outlays compressed bottom-line margins.

Read more: Perma-Pipe revenue rises 7.5% as higher factory costs and compliance outlays squeeze profits
Grafa

Teleflex Resorbable Magnesium Scaffold demonstrates sustained long-term safety in four-year study

Teleflex (NYSE:TFX) announced positive four-year follow-up data from its First-in-Human BIOMAG-I clinical trial, reinforcing the long-term safety and performance stability of its third-generation Freesolve Resorbable Magnesium Scaffold.

Read more: Teleflex Resorbable Magnesium Scaffold demonstrates sustained long-term safety in four-year study
Grafa

Cartesian Therapeutics inks licensing deal to advance in vivo autoimmune CAR-T pipeline

Cartesian Therapeutics (NASDAQ:RNAC) announced a strategic licensing agreement with WestGene Biopharma to co-develop innovative in vivo mRNA chimeric antigen receptor T-cell (CAR-T) therapies, marking a significant expansion of its clinical efforts to target severe autoimmune conditions.

Read more: Cartesian Therapeutics inks licensing deal to advance in vivo autoimmune CAR-T pipeline
Grafa
Technology

BitFuFu Bitcoin production jumps 22% as self-mining strategy expands

BitFuFu (NASDAQ:FUFU) reported a 22.1% month-over-month increase in its unaudited Bitcoin production for May 2026, driven by a deliberate pivot toward its proprietary self-mining business and stabilized infrastructure conditions across its international footprint.

Read more: BitFuFu Bitcoin production jumps 22% as self-mining strategy expands
Grafa

TG Therapeutics advances BRIUMVI beyond MS with positive myasthenia gravis data

TG Therapeutics (NASDAQ:TGTX) reported positive topline results from an early-stage clinical evaluation of a subcutaneous formulation of its flagship therapy, BRIUMVI, in patients with myasthenia gravis, marking a significant milestone in the company’s strategy to expand the drug's utility beyond its approved indication for multiple sclerosis.

Read more: TG Therapeutics advances BRIUMVI beyond MS with positive myasthenia gravis data
Grafa

RedHill's opaganib receives FDA rare pediatric disease designation for childhood cancer

RedHill Biopharma (NASDAQ:RDHL) announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation to its investigational asset, opaganib, for the treatment of neuroblastoma, a type of cancer that primarily affects infants and young children.

Read more: RedHill's opaganib receives FDA rare pediatric disease designation for childhood cancer
Grafa

Invivyd doses first participants in phase 3 COVID-19 study evaluating antibody-vaccine co-administration

Invivyd (NASDAQ:IVVD) has initiated dosing in its LIBERTY Phase 3 clinical trial, a randomized, double-blind study designed to evaluate the safety, tolerability, and immunology of its investigational monoclonal antibody candidate, VYD2311, alone and co-administered with an mRNA COVID-19 vaccine in healthy adults.

Read more: Invivyd doses first participants in phase 3 COVID-19 study evaluating antibody-vaccine co-administration

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift